glycine has been researched along with Parkinson Disease in 114 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our objective was to precisely assess changes in α-syn levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines following acute exposure to pesticides (rotenone, paraquat, maneb, and glyphosate) using Western blot and flow cytometry." | 3.79 | Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. ( Andrieu, T; Baron, T; Bétemps, D; Chorfa, A; Hogeveen, K; Lazizzera, C; Morignat, E, 2013) |
| "Concentrations of putative neuroactive substances glutamate, aspartate, gamma-aminobutyric acid, glycine, proline and ethanolamine were determined in ventricular cerebrospinal fluid collected in patients suffering from Parkinson's disease, pain syndromes or cerebellar tremor." | 3.67 | Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. ( Amsler, U; Cuénod, M; Perschak, H; Siegfried, J; Vischer, A, 1987) |
| " The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls." | 2.74 | Cysteine elevation in levodopa-treated patients with Parkinson's disease. ( Kuhn, W; Müller, T, 2009) |
| "Conversely, cataplexy, one of the key symptoms of narcolepsy, is a striking sudden episode of muscle weakness triggered by emotions during wakefulness, and comparable to REM sleep atonia." | 2.47 | The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. ( Clément, O; Fort, P; Gervasoni, D; Léger, L; Luppi, PH; Peyron, C; Salvert, D; Sapin, E, 2011) |
| " So far it is not clear whether NMDA receptor antagonists including glycine antagonists would be suitable for chronic administration because of their effects on cognition, learning and motor function." | 2.40 | The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. ( Dannhardt, G; Kohl, BK, 1998) |
| "All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer." | 1.42 | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. ( Aasly, J; Agalliu, I; Bressman, S; Friedman, E; Giladi, N; Hassin-Baer, S; Inzelberg, R; Marti-Masso, JF; Mirelman, A; Orr-Urtreger, A; Ruiz-Martinez, J; San Luciano, M; Saunders-Pullman, R; Waro, B, 2015) |
| "Patients with Parkinson's disease have reduced gray matter volume and fractional anisotropy in both cortical and sub-cortical structures, yet changes in the pre-motor phase of the disease are unknown." | 1.40 | A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. ( Artzi, M; Ben Bashat, D; Bloem, BR; Bressman, S; Giladi, N; Gurevich, T; Helmich, RC; Hendler, T; Jacob, Y; Marder, K; Mirelman, A; Orr-Urtreger, A; Thaler, A; van Nuenen, BF, 2014) |
| "The phenotype of Parkinson's disease (PD) in patients with and without leucine-rich repeat kinase 2 (LRRK2) G2019S mutations reportedly is similar; however, large, uniformly evaluated series are lacking." | 1.39 | Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. ( Alcalay, RN; Bar Shira, A; Barrett, MJ; Bressman, S; Cabassa, J; Clark, L; Cote, L; Deik, A; Dorovski, T; Fahn, S; Ford, B; Gana Weisz, M; Giladi, N; Groves, M; Gurevich, T; Hunt, AL; Johannes, B; Levy, O; Louis, E; Lubarr, N; Marder, KS; Mazzoni, P; Mejia Santana, H; Miravite, J; Mirelman, A; Nichols, W; Orbe-Reilly, M; Orr-Urtreger, A; Ortega, R; Ozelius, L; Palmese, C; Pauciulo, M; Raymond, D; Roos, E; Rosado, L; Ruiz, D; Sachdev, R; San Luciano, M; Sarva, H; Saunders-Pullman, R; Severt, L; Shanker, V; Soto-Valencia, J; Swan, MC; Tang, MX; Thaler, A; Waters, C; Yasinovsky, K; Zalis, M, 2013) |
| "While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy." | 1.38 | Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. ( Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G, 2012) |
| "Parkinson's disease is a promising target of applying personalized medicine." | 1.38 | [The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients]. ( Balicza, P; Balogh, I; Bereznai, B; Dibó, G; Hidasi, E; Klivényi, P; Molnár, MJ; Takáts, A, 2012) |
| " The oral bioavailability of D-phenylglycine-L-dopa was 31." | 1.36 | Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ( Fan, YB; Lu, HH; Tsai, MC; Tsai, TH; Wang, CL; Wang, HP, 2010) |
| "UK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche." | 1.35 | Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. ( Aasly, J; Berciano, J; Bhatia, KP; Bonifati, V; Bressman, S; Brice, A; Durr, A; Falchi, M; Ferreira, JJ; Gasser, T; Goldwurm, S; Healy, DG; Kay, DM; Klein, C; Lang, AE; Lees, AJ; Lynch, T; Marras, C; O'Sullivan, SS; Schapira, AH; Tolosa, E; Williams, DR; Wood, NW; Wszolek, ZK; Zabetian, CP, 2008) |
| "The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms." | 1.35 | Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. ( Benecke, R; Berg, D; Bonifati, V; Brown, L; Cras, P; De Deyn, PP; Engelborghs, S; Farrer, MJ; Foroud, T; Gaig, C; Gasser, T; Gibson, JM; Goldwurm, S; Guidi, M; Hagenah, J; Haugarvoll, K; Kachergus, JM; Klein, C; Nichols, WC; Nuytemans, K; Pals, P; Pickut, B; Rademakers, R; Riboldazzi, G; Ross, OA; Samii, A; Tan, EK; Theuns, J; Tolosa, E; Uitti, RJ; Van Broeckhoven, C; Walter, U; Wszolek, ZK; Zabetian, CP, 2008) |
| " Comparisons between individuals with heterozygous and homozygous LRRK2 mutations suggested that gene dosage was not correlated with phenotypic differences; however, the estimated penetrance was greater in homozygotes across all age groups." | 1.34 | Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. ( Akkari, PA; Amouri, R; Ben Sassi, S; Ben Yahmed, S; Burn, DJ; El Euch-Fayeche, G; Elango, R; Freeman, A; Gibson, RA; Gouider-Khouja, N; Hattori, N; Hentati, F; Hunter, C; Ishihara, L; Jankovic, J; Kefi, M; Leppert, D; Lyons, K; Middleton, L; Nance, M; Pahwa, R; Ragone, L; Reeves, KH; Surh, L; Swartz, JE; Thomas, S; Warren, L; Watts, RL; Wielinski, C; Zouari, M, 2007) |
| "Parkinson disease related to LRRK2 is characterized by typical clinical features, and the similarities between patients with homozygous and heterozygous mutations do not support a gene dosage effect." | 1.33 | Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. ( Amouri, R; Brice, A; Dürr, A; Farrer, MJ; Foroud, TM; Gibson, R; Griffith, A; Hattori, N; Hentati, F; Ishihara, L; Leppert, D; Lesage, S; Middleton, L; Nichols, WC; Tazir, M; Uitti, RJ; Warren, L; Watts, R; Wszolek, ZK; Zabetian, CP, 2006) |
| "The R1441G mutation causes a form of Parkinson's disease that is equivalent to that observed in idiopathic Parkinson's disease." | 1.33 | Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. ( López de Munain, A; Martí-Massó, JF; Martínez-Gil, A; Paisán-Ruiz, C; Pérez-Tur, J; Ruiz-Martínez, J; Sáenz, A; Sánchez-Mut, JV; Simón-Sánchez, J; Singleton, AB, 2006) |
| "A total of 956 individuals with Parkinson's disease (PD) from 430 multiplex PD pedigrees were screened for 12 previously reported, pathogenic LRRK2 mutations: R793M, L1114L, I1371V, R1441C, R1441G, R1441H, Y1699C, M1869T, I2012T, I2020T, G2385R, and IVS31 +3G > A." | 1.33 | Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. ( Elsaesser, VE; Foroud, T; Halter, CA; Marek, DK; Nichols, WC; Pankratz, N; Pauciulo, MW; Rudolph, A; Shults, CW, 2006) |
| "The Unified Parkinson's disease rating scale (UPDRS) was also completed." | 1.32 | Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. ( Athanassiadou, A; Ellul, J; Papadimitriou, A; Papapetropoulos, S; Papapetropoulos, T; Paschalis, C, 2003) |
| "In the search for a therapy of Parkinson's disease, ionotropic, mainly NMDA, receptor antagonists were found to have moderately beneficial, yet also some undesirable side-effects." | 1.31 | The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. ( Konieczny, J; Lorenc-Koci, E; Ossowska, K; Pilc, A; Wolfarth, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (7.02) | 18.7374 |
| 1990's | 9 (7.89) | 18.2507 |
| 2000's | 55 (48.25) | 29.6817 |
| 2010's | 37 (32.46) | 24.3611 |
| 2020's | 5 (4.39) | 2.80 |
| Authors | Studies |
|---|---|
| Zagare, A | 1 |
| Barmpa, K | 1 |
| Smajic, S | 1 |
| Smits, LM | 1 |
| Grzyb, K | 1 |
| Grünewald, A | 1 |
| Skupin, A | 1 |
| Nickels, SL | 1 |
| Schwamborn, JC | 1 |
| Fujimaki, A | 1 |
| Ohuchi, K | 1 |
| Takizawa, S | 1 |
| Murakami, T | 1 |
| Kurita, H | 1 |
| Hozumi, I | 1 |
| Wen, X | 1 |
| Kitamura, Y | 1 |
| Wu, Z | 1 |
| Maekawa, Y | 1 |
| Inden, M | 1 |
| Egger, F | 1 |
| Jakab, M | 1 |
| Fuchs, J | 1 |
| Oberascher, K | 1 |
| Brachtl, G | 1 |
| Ritter, M | 1 |
| Kerschbaum, HH | 1 |
| Gaisberger, M | 1 |
| Eldeeb, MA | 1 |
| Ragheb, MA | 1 |
| Yue, D | 1 |
| Zeng, C | 1 |
| Okyere, SK | 1 |
| Chen, Z | 1 |
| Hu, Y | 1 |
| Lee, AJ | 1 |
| Wang, Y | 1 |
| Alcalay, RN | 2 |
| Mejia-Santana, H | 1 |
| Saunders-Pullman, R | 6 |
| Bressman, S | 7 |
| Corvol, JC | 1 |
| Brice, A | 6 |
| Lesage, S | 5 |
| Mangone, G | 1 |
| Tolosa, E | 6 |
| Pont-Sunyer, C | 2 |
| Vilas, D | 1 |
| Schüle, B | 3 |
| Kausar, F | 3 |
| Foroud, T | 4 |
| Berg, D | 2 |
| Brockmann, K | 1 |
| Goldwurm, S | 6 |
| Siri, C | 1 |
| Asselta, R | 1 |
| Ruiz-Martinez, J | 5 |
| Mondragón, E | 2 |
| Marras, C | 5 |
| Ghate, T | 3 |
| Giladi, N | 4 |
| Mirelman, A | 4 |
| Marder, K | 2 |
| Vermilyea, SC | 1 |
| Emborg, ME | 1 |
| Mestre, TA | 2 |
| Visanji, NP | 2 |
| Connolly, BS | 2 |
| Gasca-Salas, C | 2 |
| Kern, DS | 2 |
| Jain, J | 2 |
| Slow, EJ | 2 |
| Faust-Socher, A | 2 |
| Kasten, M | 1 |
| Wadia, PM | 1 |
| Zadikoff, C | 1 |
| Kumar, P | 1 |
| de Bie, RM | 1 |
| Thomsen, T | 1 |
| Lang, AE | 4 |
| Klein, C | 6 |
| Eriguchi, M | 1 |
| Iida, K | 1 |
| Ikeda, S | 1 |
| Osoegawa, M | 1 |
| Nishioka, K | 1 |
| Hattori, N | 3 |
| Nagayama, H | 1 |
| Hara, H | 1 |
| Creed, RB | 1 |
| Menalled, L | 1 |
| Casey, B | 1 |
| Dave, KD | 1 |
| Janssens, HB | 1 |
| Veinbergs, I | 1 |
| van der Hart, M | 1 |
| Rassoulpour, A | 1 |
| Goldberg, MS | 1 |
| Heresco-Levy, U | 1 |
| Shoham, S | 1 |
| Javitt, DC | 1 |
| Chorfa, A | 1 |
| Bétemps, D | 1 |
| Morignat, E | 1 |
| Lazizzera, C | 1 |
| Hogeveen, K | 1 |
| Andrieu, T | 1 |
| Baron, T | 1 |
| Mamais, A | 1 |
| Raja, M | 1 |
| Manzoni, C | 1 |
| Dihanich, S | 1 |
| Lees, A | 1 |
| Moore, D | 1 |
| Lewis, PA | 1 |
| Bandopadhyay, R | 1 |
| Gao, C | 1 |
| Pang, H | 1 |
| Luo, XG | 1 |
| Ren, Y | 1 |
| Shang, H | 1 |
| He, ZY | 1 |
| Tang, MX | 1 |
| Mejia Santana, H | 1 |
| Raymond, D | 4 |
| Roos, E | 1 |
| Orbe-Reilly, M | 1 |
| Gurevich, T | 2 |
| Bar Shira, A | 1 |
| Gana Weisz, M | 1 |
| Yasinovsky, K | 1 |
| Zalis, M | 1 |
| Thaler, A | 2 |
| Deik, A | 1 |
| Barrett, MJ | 1 |
| Cabassa, J | 2 |
| Groves, M | 2 |
| Hunt, AL | 1 |
| Lubarr, N | 1 |
| San Luciano, M | 3 |
| Miravite, J | 1 |
| Palmese, C | 2 |
| Sachdev, R | 1 |
| Sarva, H | 1 |
| Severt, L | 1 |
| Shanker, V | 2 |
| Swan, MC | 1 |
| Soto-Valencia, J | 1 |
| Johannes, B | 1 |
| Ortega, R | 1 |
| Fahn, S | 1 |
| Cote, L | 1 |
| Waters, C | 1 |
| Mazzoni, P | 1 |
| Ford, B | 1 |
| Louis, E | 1 |
| Levy, O | 1 |
| Rosado, L | 1 |
| Ruiz, D | 1 |
| Dorovski, T | 1 |
| Pauciulo, M | 1 |
| Nichols, W | 1 |
| Orr-Urtreger, A | 3 |
| Ozelius, L | 3 |
| Clark, L | 1 |
| Marder, KS | 1 |
| Melamed, E | 1 |
| Artzi, M | 1 |
| Jacob, Y | 1 |
| Helmich, RC | 1 |
| van Nuenen, BF | 1 |
| Bloem, BR | 1 |
| Hendler, T | 1 |
| Ben Bashat, D | 1 |
| Chou, JS | 1 |
| Chen, CY | 1 |
| Chen, YL | 1 |
| Weng, YH | 1 |
| Yeh, TH | 1 |
| Lu, CS | 1 |
| Chang, YM | 1 |
| Wang, HL | 1 |
| Yahalom, G | 2 |
| Orlev, Y | 1 |
| Cohen, OS | 2 |
| Kozlova, E | 2 |
| Friedman, E | 3 |
| Inzelberg, R | 3 |
| Hassin-Baer, S | 3 |
| Estanga, A | 1 |
| Rodriguez-Oroz, MC | 1 |
| Barandiaran, M | 1 |
| Gorostidi, A | 2 |
| Bergareche, A | 2 |
| Lopez de Munain, A | 3 |
| Marti-Masso, JF | 3 |
| Agalliu, I | 1 |
| Waro, B | 1 |
| Aasly, J | 2 |
| Tsika, E | 1 |
| Nguyen, AP | 1 |
| Dusonchet, J | 1 |
| Colin, P | 1 |
| Schneider, BL | 1 |
| Moore, DJ | 1 |
| Cao, M | 1 |
| Gu, ZQ | 1 |
| Li, Y | 1 |
| Zhang, H | 1 |
| Dan, XJ | 1 |
| Cen, SS | 1 |
| Li, DW | 1 |
| Chan, P | 1 |
| Xu, S | 1 |
| Liu, J | 1 |
| Yang, X | 1 |
| Qian, Y | 1 |
| Xiao, Q | 1 |
| Bhudhikanok, GS | 1 |
| Udupa, K | 1 |
| AlDakheel, A | 1 |
| Kim, S | 1 |
| Azhu Valappil, R | 1 |
| Rogaeva, E | 2 |
| William Langston, J | 1 |
| Tanner, CM | 1 |
| Goldman, SM | 1 |
| Hoepken, HH | 1 |
| Gispert, S | 1 |
| Azizov, M | 1 |
| Klinkenberg, M | 1 |
| Ricciardi, F | 1 |
| Kurz, A | 1 |
| Morales-Gordo, B | 1 |
| Bonin, M | 1 |
| Riess, O | 2 |
| Gasser, T | 3 |
| Kögel, D | 1 |
| Steinmetz, H | 1 |
| Auburger, G | 2 |
| Hulihan, MM | 2 |
| Ishihara-Paul, L | 1 |
| Kachergus, J | 1 |
| Warren, L | 3 |
| Amouri, R | 3 |
| Elango, R | 2 |
| Prinjha, RK | 1 |
| Upmanyu, R | 1 |
| Kefi, M | 2 |
| Zouari, M | 2 |
| Sassi, SB | 1 |
| Yahmed, SB | 1 |
| El Euch-Fayeche, G | 2 |
| Matthews, PM | 1 |
| Middleton, LT | 1 |
| Gibson, RA | 2 |
| Hentati, F | 3 |
| Farrer, MJ | 8 |
| Healy, DG | 1 |
| Falchi, M | 1 |
| O'Sullivan, SS | 1 |
| Bonifati, V | 4 |
| Durr, A | 5 |
| Zabetian, CP | 6 |
| Ferreira, JJ | 1 |
| Kay, DM | 3 |
| Williams, DR | 1 |
| Wszolek, ZK | 3 |
| Berciano, J | 2 |
| Schapira, AH | 2 |
| Lynch, T | 2 |
| Bhatia, KP | 1 |
| Lees, AJ | 1 |
| Wood, NW | 1 |
| Elbaz, A | 1 |
| De Rosa, A | 1 |
| Criscuolo, C | 1 |
| Mancini, P | 1 |
| De Martino, M | 1 |
| Giordano, IA | 1 |
| Pappatà, S | 1 |
| Filla, A | 1 |
| De Michele, G | 1 |
| Lohmann, E | 3 |
| Leclere, L | 2 |
| De Anna, F | 1 |
| Dubois, B | 1 |
| Agid, Y | 2 |
| Patra, B | 1 |
| Parsian, AJ | 1 |
| Racette, BA | 2 |
| Zhao, JH | 1 |
| Perlmutter, JS | 2 |
| Parsian, A | 1 |
| Floris, G | 1 |
| Cannas, A | 1 |
| Solla, P | 1 |
| Murru, MR | 1 |
| Tranquilli, S | 1 |
| Corongiu, D | 1 |
| Rolesu, M | 1 |
| Cuccu, S | 1 |
| Sardu, C | 1 |
| Marrosu, F | 1 |
| Marrosu, MG | 1 |
| Zarranz, JJ | 1 |
| Gómez-Esteban, JC | 2 |
| Latourelle, JC | 1 |
| Sun, M | 1 |
| Lew, MF | 1 |
| Suchowersky, O | 1 |
| Golbe, LI | 1 |
| Mark, MH | 1 |
| Growdon, JH | 1 |
| Wooten, GF | 1 |
| Watts, RL | 2 |
| Guttman, M | 1 |
| Ahmed, A | 1 |
| Shill, HA | 1 |
| Singer, C | 2 |
| Pezzoli, G | 3 |
| Zini, M | 3 |
| Saint-Hilaire, MH | 1 |
| Hendricks, AE | 1 |
| Williamson, S | 1 |
| Nagle, MW | 1 |
| Wilk, JB | 1 |
| Massood, T | 1 |
| Huskey, KW | 1 |
| Laramie, JM | 1 |
| DeStefano, AL | 1 |
| Baker, KB | 1 |
| Itin, I | 1 |
| Litvan, I | 1 |
| Nicholson, G | 1 |
| Corbett, A | 1 |
| Nance, M | 2 |
| Drasby, E | 1 |
| Isaacson, S | 1 |
| Burn, DJ | 2 |
| Chinnery, PF | 1 |
| Pramstaller, PP | 1 |
| Al-hinti, J | 1 |
| Moller, AT | 1 |
| Ostergaard, K | 1 |
| Sherman, SJ | 1 |
| Roxburgh, R | 1 |
| Snow, B | 1 |
| Slevin, JT | 1 |
| Cambi, F | 1 |
| Gusella, JF | 1 |
| Myers, RH | 1 |
| Blekher, T | 1 |
| Weaver, M | 1 |
| Rupp, J | 1 |
| Nichols, WC | 4 |
| Hui, SL | 1 |
| Gray, J | 1 |
| Yee, RD | 1 |
| Wojcieszek, J | 1 |
| Müller, T | 1 |
| Kuhn, W | 1 |
| Yamamoto, M | 1 |
| Lopez, AN | 1 |
| Ujike, H | 1 |
| Mata, IF | 1 |
| Izumi, Y | 1 |
| Kaji, R | 1 |
| Maruyama, H | 1 |
| Morino, H | 1 |
| Oda, M | 1 |
| Hutter, CM | 1 |
| Edwards, KL | 1 |
| Schellenberg, GD | 1 |
| Tsuang, DW | 1 |
| Yearout, D | 1 |
| Larson, EB | 1 |
| Kawakami, H | 1 |
| Paus, S | 1 |
| Gadow, F | 1 |
| Knapp, M | 1 |
| Klockgether, T | 1 |
| Wüllner, U | 1 |
| Kim, JM | 1 |
| Lee, JY | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| Shin, ES | 1 |
| Cho, JH | 1 |
| Park, SS | 1 |
| Jeon, BS | 1 |
| Mao, XY | 1 |
| Burgunder, JM | 3 |
| Zhang, ZJ | 3 |
| Chang, XL | 1 |
| Peng, R | 2 |
| Yang, Y | 1 |
| Wang, YC | 2 |
| Li, T | 2 |
| Gomez, A | 1 |
| Ferrer, I | 1 |
| Benamer, HT | 1 |
| de Silva, R | 1 |
| Miyake, Y | 1 |
| Tsuboi, Y | 1 |
| Koyanagi, M | 1 |
| Fujimoto, T | 1 |
| Shirasawa, S | 1 |
| Kiyohara, C | 1 |
| Tanaka, K | 1 |
| Fukushima, W | 1 |
| Sasaki, S | 1 |
| Yamada, T | 1 |
| Oeda, T | 1 |
| Miki, T | 1 |
| Kawamura, N | 1 |
| Sakae, N | 1 |
| Fukuyama, H | 1 |
| Hirota, Y | 1 |
| Nagai, M | 1 |
| Ibañez, B | 1 |
| Alzualde, A | 1 |
| Otaegui, D | 1 |
| Moreno, F | 1 |
| Martí Massó, JF | 1 |
| Wang, CL | 1 |
| Fan, YB | 1 |
| Lu, HH | 1 |
| Tsai, TH | 1 |
| Tsai, MC | 1 |
| Wang, HP | 1 |
| Yamamoto-Watanabe, Y | 1 |
| Watanabe, M | 1 |
| Jackson, M | 1 |
| Akimoto, H | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Wakasaya, Y | 1 |
| Matsubara, E | 1 |
| Kawarabayashi, T | 1 |
| Harigaya, Y | 1 |
| Lyndon, AR | 1 |
| Shoji, M | 1 |
| Luppi, PH | 1 |
| Clément, O | 1 |
| Sapin, E | 1 |
| Gervasoni, D | 1 |
| Peyron, C | 1 |
| Léger, L | 1 |
| Salvert, D | 1 |
| Fort, P | 1 |
| Valldeoriola, F | 2 |
| Gaig, C | 3 |
| Muxí, A | 1 |
| Navales, I | 1 |
| Paredes, P | 1 |
| Lomeña, F | 1 |
| De la Cerda, A | 1 |
| Buongiorno, M | 1 |
| Ezquerra, M | 2 |
| Santacruz, P | 1 |
| Martí, MJ | 2 |
| Brüggemann, N | 1 |
| Hagenah, J | 2 |
| Stanley, K | 2 |
| Wang, C | 1 |
| Ozelius, LJ | 1 |
| Bressman, SB | 1 |
| Heiman, G | 1 |
| Tunesi, S | 1 |
| Tesei, S | 2 |
| Sironi, F | 2 |
| Primignani, P | 1 |
| Magnani, C | 1 |
| Kaplan, N | 1 |
| Vituri, A | 1 |
| Korczyn, AD | 1 |
| Rosset, S | 1 |
| Balicza, P | 1 |
| Bereznai, B | 1 |
| Takáts, A | 1 |
| Klivényi, P | 1 |
| Dibó, G | 1 |
| Hidasi, E | 1 |
| Balogh, I | 1 |
| Molnár, MJ | 1 |
| Sierra, M | 1 |
| Sánchez-Juan, P | 1 |
| Martínez-Rodríguez, MI | 1 |
| González-Aramburu, I | 1 |
| García-Gorostiaga, I | 1 |
| Quirce, MR | 1 |
| Palacio, E | 1 |
| Carril, JM | 1 |
| Combarros, O | 1 |
| Infante, J | 1 |
| García-Lozano, JR | 1 |
| Mir, P | 1 |
| Alberca, R | 1 |
| Aguilera, I | 1 |
| Gil Néciga, E | 1 |
| Fernández-López, O | 1 |
| Cayuela, A | 1 |
| Núñez-Roldan, A | 1 |
| Poisik, OV | 1 |
| Mannaioni, G | 1 |
| Traynelis, S | 1 |
| Smith, Y | 1 |
| Conn, PJ | 1 |
| Holzmann, C | 1 |
| Krüger, R | 1 |
| Saecker, AM | 1 |
| Schmitt, I | 1 |
| Schöls, L | 1 |
| Berger, K | 1 |
| Papapetropoulos, S | 2 |
| Ellul, J | 1 |
| Paschalis, C | 1 |
| Athanassiadou, A | 1 |
| Papadimitriou, A | 1 |
| Papapetropoulos, T | 1 |
| Zekanowski, C | 1 |
| Pepłońska, B | 1 |
| Styczyńska, M | 1 |
| Religa, D | 1 |
| Pfeffer, A | 1 |
| Czyzewski, K | 1 |
| Gabryelewicz, T | 1 |
| Szybińska, A | 1 |
| Kijanowska-Haładyna, B | 1 |
| Kotapka-Minc, S | 1 |
| Łuczywek, E | 1 |
| Barczak, A | 1 |
| Wasiak, B | 1 |
| Chodakowska-Zebrowska, M | 1 |
| Przekop, I | 1 |
| Kuźnicki, J | 1 |
| Barcikowska, M | 1 |
| Hernandez, DG | 1 |
| Paisán-Ruíz, C | 2 |
| McInerney-Leo, A | 2 |
| Jain, S | 1 |
| Meyer-Lindenberg, A | 1 |
| Evans, EW | 1 |
| Berman, KF | 1 |
| Johnson, J | 1 |
| Schäffer, AA | 1 |
| Lopez, GJ | 1 |
| Nussbaum, RL | 1 |
| Singleton, AB | 2 |
| Passey, S | 1 |
| Domenici, MR | 1 |
| Potenza, RL | 1 |
| Martire, A | 1 |
| Coccurello, R | 1 |
| Pèzzola, A | 1 |
| Reggio, R | 1 |
| Tebano, MT | 1 |
| Popoli, P | 1 |
| Kramer, P | 2 |
| Higgins, D | 1 |
| Payami, H | 2 |
| Bras, JM | 1 |
| Guerreiro, RJ | 1 |
| Ribeiro, MH | 1 |
| Januario, C | 1 |
| Morgadinho, A | 1 |
| Oliveira, CR | 1 |
| Cunha, L | 1 |
| Hardy, J | 1 |
| Singleton, A | 1 |
| Ibanez, P | 1 |
| Pollak, P | 1 |
| Tison, F | 1 |
| Tazir, M | 2 |
| Leutenegger, AL | 1 |
| Guimaraes, J | 1 |
| Bonnet, AM | 1 |
| Factor, SA | 1 |
| Nutt, JG | 1 |
| Samii, A | 2 |
| Griffith, A | 2 |
| Bird, TD | 1 |
| Higgins, DS | 1 |
| Giasson, BI | 1 |
| Covy, JP | 1 |
| Bonini, NM | 1 |
| Hurtig, HI | 1 |
| Trojanowski, JQ | 1 |
| Van Deerlin, VM | 1 |
| Muñoz, E | 1 |
| Williams-Gray, CH | 1 |
| Goris, A | 1 |
| Foltynie, T | 1 |
| Brown, J | 1 |
| Maranian, M | 1 |
| Walton, A | 1 |
| Compston, DA | 1 |
| Sawcer, SJ | 1 |
| Barker, RA | 1 |
| Ossowska, K | 2 |
| Konieczny, J | 2 |
| Wardas, J | 1 |
| Pietraszek, M | 1 |
| Kuter, K | 1 |
| Wolfarth, S | 2 |
| Pilc, A | 2 |
| Ross, OA | 4 |
| Toft, M | 2 |
| Johnson, JL | 1 |
| Mash, DC | 1 |
| Ishihara, L | 2 |
| Gibson, R | 1 |
| Uitti, RJ | 2 |
| Leppert, D | 2 |
| Watts, R | 1 |
| Foroud, TM | 1 |
| Middleton, L | 2 |
| Simón-Sánchez, J | 1 |
| Sánchez-Mut, JV | 1 |
| Martínez-Gil, A | 1 |
| Sáenz, A | 1 |
| Pérez-Tur, J | 1 |
| Pchelina, SN | 1 |
| Yakimovskii, AF | 1 |
| Ivanova, ON | 1 |
| Emelianov, AK | 1 |
| Zakharchuk, AH | 1 |
| Schwarzman, AL | 1 |
| Pankratz, N | 1 |
| Pauciulo, MW | 1 |
| Elsaesser, VE | 1 |
| Marek, DK | 1 |
| Halter, CA | 1 |
| Rudolph, A | 1 |
| Shults, CW | 1 |
| Tan, EK | 5 |
| Skipper, L | 1 |
| Tan, L | 2 |
| Liu, JJ | 2 |
| Gosal, D | 1 |
| Haugarvoll, K | 3 |
| Gibson, JM | 2 |
| Deng, H | 1 |
| Le, W | 1 |
| Guo, Y | 1 |
| Hunter, CB | 1 |
| Xie, W | 1 |
| Huang, M | 1 |
| Jankovic, J | 2 |
| Lyons, K | 1 |
| Wielinski, C | 1 |
| Hunter, C | 1 |
| Swartz, JE | 1 |
| Akkari, PA | 1 |
| Surh, L | 1 |
| Reeves, KH | 1 |
| Thomas, S | 1 |
| Ragone, L | 1 |
| Pahwa, R | 1 |
| Freeman, A | 1 |
| Gouider-Khouja, N | 1 |
| Ben Sassi, S | 1 |
| Ben Yahmed, S | 1 |
| Horvath, R | 1 |
| Kley, RA | 1 |
| Lochmüller, H | 1 |
| Vorgerd, M | 1 |
| Mariani, L | 1 |
| Miceli, R | 1 |
| Clementi, M | 1 |
| Stone, JT | 1 |
| Lin, CH | 1 |
| Dächsel, JC | 1 |
| Wu, RM | 1 |
| Fook-Chong, S | 2 |
| Yi, Z | 1 |
| White, LR | 1 |
| Kvam, SN | 1 |
| Aasly, JO | 1 |
| Huang, Y | 1 |
| Halliday, GM | 1 |
| Vandebona, H | 1 |
| Mellick, GD | 1 |
| Mastaglia, F | 1 |
| Stevens, J | 1 |
| Kwok, J | 1 |
| Garlepp, M | 1 |
| Silburn, PA | 1 |
| Horne, MK | 1 |
| Kotschet, K | 1 |
| Venn, A | 1 |
| Rowe, DB | 1 |
| Rubio, JP | 1 |
| Sue, CM | 1 |
| Borg, M | 1 |
| Ruberg, M | 1 |
| Zhao, Y | 1 |
| Lim, HQ | 1 |
| Lee, J | 1 |
| Yuen, Y | 1 |
| Pavanni, R | 1 |
| Wong, MC | 1 |
| Kalinderi, K | 1 |
| Fidani, L | 1 |
| Bostantjopoulou, S | 1 |
| Katsarou, Z | 1 |
| Kotsis, A | 1 |
| Munhoz, RP | 1 |
| Wakutani, Y | 1 |
| Teive, HA | 1 |
| Raskin, S | 1 |
| Werneck, LC | 1 |
| Moreno, D | 1 |
| Sato, C | 1 |
| An, XK | 1 |
| Wu, Y | 1 |
| Chen, WJ | 1 |
| Zhang, JH | 1 |
| Xu, YM | 1 |
| Gou, YR | 1 |
| Yuan, GG | 1 |
| Rademakers, R | 1 |
| Kachergus, JM | 1 |
| Nuytemans, K | 1 |
| Guidi, M | 1 |
| Riboldazzi, G | 1 |
| Brown, L | 1 |
| Walter, U | 1 |
| Benecke, R | 1 |
| Theuns, J | 1 |
| Pals, P | 1 |
| Cras, P | 1 |
| De Deyn, PP | 1 |
| Engelborghs, S | 1 |
| Pickut, B | 1 |
| Van Broeckhoven, C | 1 |
| Schägger, H | 1 |
| Carroll, CB | 1 |
| Holloway, V | 1 |
| Brotchie, JM | 1 |
| Mitchell, IJ | 1 |
| Ball, EF | 1 |
| Shaw, PJ | 1 |
| Ince, PG | 1 |
| Johnson, M | 1 |
| Youdim, MB | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Vargas, C | 1 |
| Gómez, P | 1 |
| Navarro, JA | 1 |
| Benito-León, J | 1 |
| Ortí-Pareja, M | 1 |
| Gasalla, T | 1 |
| Cisneros, E | 1 |
| Arenas, J | 1 |
| Dannhardt, G | 1 |
| Kohl, BK | 1 |
| Han, J | 1 |
| Cheng, FC | 1 |
| Yang, Z | 1 |
| Dryhurst, G | 1 |
| Lorenc-Koci, E | 1 |
| Iwasaki, Y | 1 |
| Ikeda, K | 1 |
| Shiojima, T | 1 |
| Kinoshita, M | 1 |
| Vamvakidès, A | 1 |
| Perschak, H | 1 |
| Amsler, U | 1 |
| Vischer, A | 1 |
| Siegfried, J | 1 |
| Cuénod, M | 1 |
| Gründig, E | 4 |
| Gerstenbrand, F | 3 |
| Oberhummer, J | 1 |
| Simanyi, M | 1 |
| Schedl, R | 1 |
| Weiss, J | 1 |
| McGeer, PL | 1 |
| McGeer, EG | 1 |
| Chase, TN | 1 |
| Woods, AC | 1 |
| Lipton, MA | 1 |
| Morris, CE | 1 |
| Kastin, AJ | 1 |
| Barbeau, A | 1 |
| Hanbauer, I | 1 |
| Bruck, J | 1 |
| Gnad, H | 1 |
| Prosenz, P | 1 |
| Teuflmayr, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The DNA and Cell Bank of IFR of Neurosciences: Clinical and Genetic Study of Parkinson's Disease and Epilepsies[NCT00142363] | 1,700 participants | Observational | 2004-05-31 | Terminated | |||
| Parkin Mutations and Their Functional Consequences[NCT00136721] | 2,500 participants | Observational | 2002-06-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for glycine and Parkinson Disease
| Article | Year |
|---|---|
N-degron-mediated degradation and regulation of mitochondrial PINK1 kinase.
Topics: Animals; Glycine; Metabolic Networks and Pathways; Mitochondria; Mitochondrial Membranes; Mitochondr | 2020 |
In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Topics: Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mitochondria; Mutation; Park | 2018 |
Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Glycine; Humans; Parkinson Disease; Recep | 2013 |
LRRK2 G2019S in the North African population: a review.
Topics: Africa, Northern; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Rich Repeat Serine-Thr | 2010 |
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder.
Topics: Amygdala; Animals; Brain; Brain Mapping; Cataplexy; Emotions; gamma-Aminobutyric Acid; Glutamine; Gl | 2011 |
An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats.
Topics: Animals; Benzoates; Catalepsy; Corpus Striatum; Enkephalins; Excitatory Amino Acid Antagonists; Glut | 2007 |
LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.
Topics: Alleles; Amino Acid Substitution; Asia; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protei | 2007 |
The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications.
Topics: Alzheimer Disease; Animals; Binding Sites; Cerebrovascular Disorders; Epilepsy; Glycine; Humans; Neu | 1998 |
[Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
Topics: Animals; Antiparkinson Agents; gamma-Aminobutyric Acid; Glutamates; Glycine; Humans; Parkinson Disea | 1990 |
Neurotransmitter synthetic enzymes.
Topics: Acetylcholine; Acetyltransferases; Adenylyl Cyclases; Aging; Aminobutyrates; Animals; Brain; Brain C | 1973 |
1 trial available for glycine and Parkinson Disease
| Article | Year |
|---|---|
Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cysteine; Female; Glycine; | 2009 |
103 other studies available for glycine and Parkinson Disease
| Article | Year |
|---|---|
Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression.
Topics: Amino Acid Substitution; Amyloid beta-Protein Precursor; Carrier Proteins; Cell Differentiation; Cyt | 2022 |
The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells.
Topics: alpha-Synuclein; Glycine; Humans; Hypoxia; Neuroprotective Agents; Oxidative Stress; Parkinson Disea | 2023 |
Effect of Glycine on BV-2 Microglial Cells Treated with Interferon-γ and Lipopolysaccharide.
Topics: Alzheimer Disease; Animals; Antigens, CD; Apoptosis; Cell Line, Transformed; Glutathione; Glycine; H | 2020 |
Glycine nano-selenium prevents brain oxidative stress and neurobehavioral abnormalities caused by MPTP in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Behavior, Animal; Brain | 2021 |
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Family Health; Female; Gene Frequency; Genetic Predi | 2017 |
Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Family; Family Health; Female; Glycine; Humans | 2018 |
Parkinsonism Relating to Intoxication with Glyphosate.
Topics: Adult; Glycine; Glyphosate; Herbicides; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle R | 2019 |
Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
Topics: Acetylcholine; Animals; Brain; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Gene Knockou | 2019 |
Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
Topics: alpha-Synuclein; Cell Death; Cell Line, Tumor; Cell Survival; Glycine; Glyphosate; Humans; Insectici | 2013 |
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Brain; Female; Gene Expression Regulation; Glycine; Humans | 2013 |
LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation.
Topics: Aged; Female; Genotype; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male | 2013 |
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Topics: Aged; Female; Genotype; Glycine; Humans; Jews; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2013 |
The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
Topics: Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mutation; Park | 2013 |
A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Topics: Adult; Brain; Cognition Disorders; Diffusion Tensor Imaging; Female; Glycine; Humans; Leucine-Rich R | 2014 |
(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Topics: Animals; Apomorphine; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; GAB | 2014 |
Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
Topics: Aged; Disease Progression; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glyc | 2014 |
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Case-Control Studies; Cognition Disorders; Female; Glycine | 2014 |
Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Topics: Aged; Aged, 80 and over; Europe; Female; Genetic Association Studies; Genetic Predisposition to Dise | 2015 |
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Topics: Adenoviridae; alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Female; Forelimb; G | 2015 |
Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
Topics: Aged; Aged, 80 and over; Arginine; Female; Genetic Predisposition to Disease; Genotype; Glycine; Hum | 2016 |
Association of the DRD2 CA
Topics: Aged; Aged, 80 and over; Analysis of Variance; Benzothiazoles; Case-Control Studies; Dinucleotide Re | 2017 |
Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
Topics: Aged; Electrocardiography; Female; Genetic Association Studies; Glycine; Heart Diseases; Heart Rate; | 2017 |
Parkinson patient fibroblasts show increased alpha-synuclein expression.
Topics: Aged; alpha-Synuclein; Aspartic Acid; Cells, Cultured; Family Health; Female; Fibroblasts; Gene Expr | 2008 |
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Topics: Age Factors; Case-Control Studies; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glyc | 2008 |
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Topics: Age Factors; Age of Onset; Case-Control Studies; DNA Mutational Analysis; Family Health; Female; Gen | 2008 |
LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
Topics: Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; | 2008 |
Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.
Topics: Adult; Age of Onset; Aged; DNA Mutational Analysis; Female; Fluorodeoxyglucose F18; Gene Frequency; | 2009 |
A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
Topics: Aged; DNA Mutational Analysis; Family Health; Female; France; Genetic Predisposition to Disease; Gly | 2009 |
LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.
Topics: Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Gene Frequency; Genetic Pred | 2009 |
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arginine; Cysteine; DNA Mutational Analysis; Female; Ge | 2009 |
LRRK2 mutations in Basque patients with Parkinson's disease.
Topics: Arginine; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinso | 2008 |
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine | 2008 |
Multiple step pattern as a biomarker in Parkinson disease.
Topics: Aged; Analysis of Variance; Attention; Biomarkers; Female; Fixation, Ocular; Glycine; Humans; Leucin | 2009 |
LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.
Topics: Aged; Arginine; DNA Mutational Analysis; Exons; Family Health; Female; Gene Frequency; Genetic Predi | 2009 |
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Community Networks; Dyskinesia, Drug-Induced; Female; | 2009 |
The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Chi-Square Distribution; Female; Gene Frequency; Genetic P | 2010 |
ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China.
Topics: Age of Onset; Alanine; China; DNA Mutational Analysis; Glycine; Humans; Parkinson Disease; Polymorph | 2010 |
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Cerebral Cortex; Cognition Disorders; Electrophoresis, Gel | 2010 |
LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: a case-control study in Japan.
Topics: Aged; Arginine; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Gen | 2010 |
Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).
Topics: Age Factors; Aged; Aged, 80 and over; Arginine; Family; Female; Glycine; Humans; Incidence; Leucine- | 2010 |
Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Dopamine; Drug Carriers; Gly | 2010 |
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biomarkers; Case | 2010 |
123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Glycine; Heart; Humans; Leucine-Rich | 2011 |
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
Topics: Adult; Age Factors; Aged; Female; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Rich R | 2011 |
LRRK2 G2019S mutations may be increased in Puerto Ricans.
Topics: Adult; Aged; Female; Glycine; Hispanic or Latino; Humans; Leucine-Rich Repeat Serine-Threonine Prote | 2011 |
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Female; Genetic Predisposition to Disease; Glycine; Hu | 2011 |
Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Glycine; Hu | 2011 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Freq | 2012 |
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
Topics: Adult; Age of Onset; Aged; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Testin | 2012 |
Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Cohort Studies; Cross-Sectional Studie | 2013 |
Mitochondrial DNA A4336G mutation in Alzheimer's and Parkinson's diseases.
Topics: Aged; Alanine; Alzheimer Disease; Case-Control Studies; DNA, Mitochondrial; Female; Glycine; Humans; | 2002 |
Distinct functional roles of the metabotropic glutamate receptors 1 and 5 in the rat globus pallidus.
Topics: Animals; Cells, Cultured; Central Nervous System; Electric Conductivity; Enzyme Inhibitors; Excitato | 2003 |
Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease.
Topics: Aged; alpha-Synuclein; Cell Culture Techniques; Cysteine; Enzyme-Linked Immunosorbent Assay; Female; | 2003 |
Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece.
Topics: Age of Onset; Aged; Aged, 80 and over; Alanine; alpha-Synuclein; DNA Mutational Analysis; Family Hea | 2003 |
The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Chi-Square Distribution; Cohort St | 2004 |
Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
Topics: Aged; Amino Acid Sequence; Animals; Dihydroxyphenylalanine; DNA Mutational Analysis; Family Health; | 2005 |
Gene mutation detected in Parkinson's disease.
Topics: Amino Acid Substitution; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mut | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Ex | 2005 |
Genetic testing in Parkinson's disease.
Topics: Female; Genetic Testing; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mal | 2005 |
Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Follow-Up Studies; G | 2005 |
G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Gene | 2005 |
G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Fr | 2005 |
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Fe | 2006 |
Biochemical and pathological characterization of Lrrk2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; Amino Acid Sequence; Animals; Blotting, Western; Br | 2006 |
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Arginine; Child; Child, Preschool; DNA Mut | 2006 |
Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Chromosome Aberrations; Cohort Studies; DNA | 2006 |
Clinical heterogeneity of the LRRK2 G2019S mutation.
Topics: Aged; Aged, 80 and over; Case-Control Studies; DNA Mutational Analysis; Female; Glycine; Humans; Leu | 2006 |
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
Topics: Aged; DNA Mutational Analysis; Family Health; Female; Gene Frequency; Genetic Predisposition to Dise | 2006 |
Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques.
Topics: Aged; Arginine; Chromosomes, Human, Pair 12; Demography; DNA Mutational Analysis; Family Health; Fem | 2006 |
G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Glycine; Humans; Leu | 2006 |
Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Family Health; Female; Genetic Testing; Glycine; Humans; | 2006 |
LRRK2 G2019S founder haplotype in the Chinese population.
Topics: Asian People; Glycine; Haplotypes; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Pa | 2007 |
Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred.
Topics: Arginine; Binding Sites; Disease Progression; Glycine; Histidine; Humans; Ireland; Leucine-Rich Repe | 2007 |
Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Topics: Adult; Aged; Arginine; Chromosomes, Human, Pair 12; DNA Mutational Analysis; Female; Glycine; Humans | 2006 |
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
Topics: Adult; Aged; Aged, 80 and over; Cross-Cultural Comparison; DNA Mutational Analysis; Family Health; F | 2007 |
Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNALys.
Topics: Aged; Alanine; Amino Acid Substitution; Glycine; Humans; Male; MERRF Syndrome; Muscle, Skeletal; Mus | 2007 |
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Geneti | 2007 |
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.
Topics: Aged; Arginine; Asian People; Female; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Ri | 2007 |
Comparing LRRK2 Gly2385Arg carriers with noncarriers.
Topics: Aged; Arginine; Female; Genetic Carrier Screening; Glycine; Humans; Leucine-Rich Repeat Serine-Threo | 2007 |
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
Topics: Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Glycine | 2007 |
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Topics: Aged; Australia; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Genetic Predisposit | 2007 |
Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
Topics: Aged; DNA Mutational Analysis; Europe; Family Health; Female; Glycine; Humans; Leucine-Rich Repeat S | 2007 |
Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Asia, Southeastern; Chi-Square Distribution; Female; Gene | 2007 |
The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Cohort Studies; Female; Glycine; Greece; Humans; L | 2007 |
The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Brazil; Diseases in Twins; Female; Glycine; Humans; Le | 2008 |
LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Asian People; Chi-Square Distribution; China; Female; Gene | 2008 |
Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant.
Topics: Arginine; Asia; Asian People; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2008 |
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Arginine; Cysteine; DNA Mutational Analysis | 2008 |
Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two-dimensional resolution: normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities.
Topics: Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Glycine; Humans; NAD(P)H | 1995 |
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding, Competitive; Corpus Striatum; Dose- | 1995 |
The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Autoradiography; Basal Ganglia; Binding Sites; Dizocilpine Mal | 1994 |
Parkinson's disease and milacemide.
Topics: Acetamides; Animals; Brain; Glycine; Humans; Macaca mulatta; Monoamine Oxidase Inhibitors; Motor Ski | 1994 |
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Asparagine; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutam | 1996 |
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 1999 |
The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity.
Topics: Animals; Bridged Bicyclo Compounds; Electromyography; Glycine; Ligands; Male; Muscle Rigidity; Parki | 2000 |
Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Female; Glutamates; Glutamic Acid; Glycine; Humans; Male; Mi | 1992 |
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Ethanolamine; Ethanolamines; Female; gamma-Aminobutyric Aci | 1987 |
[Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
Topics: Cysteine; Cystine; Dihydroxyphenylalanine; Female; Glycine; Humans; Male; Methionine; Parkinson Dise | 1972 |
Hypothalamic releasing factors and Parkinson disease.
Topics: Antiparkinson Agents; Depression, Chemical; Dihydroxyphenylalanine; Drug Therapy, Combination; Glyci | 1974 |
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Topics: Administration, Oral; Aged; Amides; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Glycine; H | 1972 |
[Correlation between Parkinsonism symptoms and a disorder in the amino acid metabolism in CNS].
Topics: Amino Acids; Animals; Brain Injuries; Central Nervous System Diseases; Cerebrospinal Fluid; Cysteine | 1970 |
[Brain aminoacids in phenothiazin-induced Parkinsonism. Drug-induced parkinsonism in the rat--a model for biochemical studies of the Parkinson-syndrome].
Topics: Amino Acids; Aminobutyrates; Animals; Basal Ganglia; Brain; Cerebellum; Cerebral Cortex; Chromatogra | 1970 |
[The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. I. Alterations of cerebrospinal fluid in patients with parkinson's disease and normals].
Topics: Alanine Transaminase; Arginine; Aspartate Aminotransferases; Dihydroxyphenylalanine; Glutamine; Glyc | 1969 |